<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736667</url>
  </required_header>
  <id_info>
    <org_study_id>MVSS</org_study_id>
    <nct_id>NCT04736667</nct_id>
  </id_info>
  <brief_title>Mitral Valve Screening Survey</brief_title>
  <acronym>MVSS</acronym>
  <official_title>Mitral Valve Screening Survey (MVSS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine the clinical profile/anatomical characteristics and natural&#xD;
      history of patients who subsequently fail screening for transcatheter mitral valve&#xD;
      intervention (TMVI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous transcatheter mitral valve interventions have emerged as a treatment option for&#xD;
      patients with mitral valve disease. Development of transcatheter mitral valve repair (TMVr)&#xD;
      and transcatheter mitral valve replacement (TMVR) continues to progress with ongoing rigorous&#xD;
      clinical trials of several experimental devices. However, despite being referred for TMVI,&#xD;
      most patients do not pass stringent screening criteria for these investigational devices and&#xD;
      are not offered TMVI.&#xD;
&#xD;
      In this prospective multicenter registry, baseline demographics, anatomical/imaging&#xD;
      characteristics, and clinical outcomes of patients who fail screening for TMVI will be&#xD;
      prospectively collected into a registry database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">February 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reason for screen failure</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days, 1 year, and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>30 days, 1 year, and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral intervention</measure>
    <time_frame>30 days, 1 year, and annually up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Mitral Valve Disease</condition>
  <arm_group>
    <arm_group_label>Subjects fail screening for TMVI</arm_group_label>
    <description>Subjects with symptomatic mitral valve disease who after referral for TMVI, are deemed not to be candidates for TMVI.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This multicenter prospective study will enroll consecutive subjects, who after referral for&#xD;
        TMVI, are deemed not to be candidates for TMVI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject failed screening for TMVI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years of age&#xD;
&#xD;
          -  Subject unable or unwilling to give informed consent&#xD;
&#xD;
          -  Subject proceeded with TMVI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jake Sutton</last_name>
    <phone>202-877-6624</phone>
    <email>joseph.a.sutton@medstar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Rowland, MPH</last_name>
    <phone>202-877-2959</phone>
    <email>megan.e.rowland@medstar.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake Sutton</last_name>
      <phone>202-877-6624</phone>
      <email>joseph.a.sutton@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Megan Rowland</last_name>
      <phone>202-877-2959</phone>
      <email>megan.e.rowland@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

